Delta-Fly Pharma (TSE:4598) Debt-to-EBITDA : N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4598 Delta-Fly Pharma Inc TSE:4598
27 GF Score
Price 円107.00
! 2 Warning Signs
View Full Analysis

What is Delta-Fly Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Delta-Fly Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was 円0.00 Mil. Delta-Fly Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was 円0.00 Mil. Delta-Fly Pharma's annualized EBITDA for the quarter that ended in Mar. 2026 was 円0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Delta-Fly Pharma's Debt-to-EBITDA or its related term are showing as below:

During the past 10 years, the highest Debt-to-EBITDA Ratio of Delta-Fly Pharma was 0.08. The lowest was -0.08. And the median was -0.01.

TSE:4598's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.39
* Ranked among companies with meaningful Debt-to-EBITDA only.

Delta-Fly Pharma  (TSE:4598) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Delta-Fly Pharma Debt-to-EBITDA Related Terms


Delta-Fly Pharma Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Delta-Fly Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delta-Fly Pharma Debt-to-EBITDA Chart

Delta-Fly Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Delta-Fly Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.00 0.00 N/A N/A

TSE:4598 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Delta-Fly Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delta-Fly Pharma Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Delta-Fly Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Delta-Fly Pharma's Debt-to-EBITDA falls into.


TSE:4598
27GF Score
Delta-Fly Pharma Inc TSE:4598
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delta-Fly Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Delta-Fly Pharma's Debt-to-EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1603.652
=0.00

Delta-Fly Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.


Delta-Fly Pharma Business Description

Address 37-5, Miyajima Nishikino, Kawauchi-cho, Tokushima, JPN, 771-0116
Delta-Fly Pharma Inc is a Japan-based company mainly engaged in the discovery and development of gentle anti-cancer agents with module technology.
27GF Score

Get the complete analysis for TSE:4598

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円107.00
Price